Literature DB >> 32072595

Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions.

Greg Ball1, Raffael Kurek2, Barbara A Hendrickson3, James Buchanan4, William W Wang5, Susan P Duke6, Amit Bhattacharyya7, Mengchun Li8, Dennis O'Brien9, Judith Weigel10, Wenquan Wang11, Qi Jiang12, Faiz Ahmad13, Jonathan H Seltzer14, Esteban Herrero-Martinez15, Lothar Tremmel16.   

Abstract

Notwithstanding successful harmonization efforts, the global regulatory framework governing product safety is complex and continually evolving, as evidenced by additional regional guidance and regulations. In this regulatory review, we provide an overview from both global and regional perspectives. A historical perspective, with a focus on recent developments, enables identification of important long-term trends, such as a shift from single-case medical review of serious adverse events to an interdisciplinary evaluation of aggregate data for the purpose of judging product causality and informing benefit-risk assessments. We will show how these trends lead to opportunities for closer interdisciplinary collaboration, for bridging the gap between preand postmarketing surveillance, and for a more proactive determination of patient populations with a positive benefit-risk profile for product use. We will conclude by pointing to ongoing and future work that seeks to provide specific solutions for ongoing aggregate safety evaluation.

Entities:  

Keywords:  RSI; SUSAR; aggregate safety assessment; interdisciplinary safety evaluation; medical judgment

Mesh:

Year:  2020        PMID: 32072595      PMCID: PMC7222952          DOI: 10.1007/s43441-019-00076-4

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  1 in total

Review 1.  Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities.

Authors:  Veronique F Kugener; Eric S Freedland; Kenneth I Maynard; Omar Aimer; Peggy S Webster; Maribel Salas; Maxine Gossell-Williams
Journal:  Drug Saf       Date:  2021-05-15       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.